On September 1 (Monday) another meeting of the Transparency Council.
AOTMiT: Transparency Council incl. about drugs for acute myeloid leukemia and diabetes
Published July 28, 2022 09:15
Źródło: AOTMiT
The agenda includes:
Preparation of drug assessment positions:
• Onureg (azacitidine) as part of the B.114 drug program. "Treatment of patients with acute myeloid leukemia (ICD-10 C 92.0)",
• Suliqua (insulinum glarginum + lixisenatidum) in the indication: treatment of adult patients with uncontrolled type 2 diabetes despite treatment with basal insulin (BI) in combination with at least one oral hypoglycaemic agent (OAD) with HbA1c> 7%,
• Tremfya (guselkumabum) under the drug program: "Treatment of active psoriatic arthritis (PsA) (ICD-10 L40.5, M07.1, M07.2, M07.3)".
Source: AOTMiT
